Biogen has sold off on fears of slowing sales of Tecfidera, the company's most successful drug. Over the next five years it is the pipeline, not existing products, that will drive Biogen's return. The ...

Biogen Inc. is a major biotech player in neurology and rare diseases, with a portfolio that spans multiple sclerosis therapies and emerging Alzheimer treatments. The company’s long-term value story ...